On January 12, Chaoshan Hecheng Hospital and Neuboron held a grand signing ceremony for cooperation on Boron Neutron Capture Therapy (BNCT) technology in Shantou City, jointly launching high-end medical services of BNCT technology in the eastern Guangdong region.
Mr. Zheng Youshui, Chairman of Chaoshan Hecheng Hospital and also Chairman of the listed company Jinlongyu Group Co., Ltd., and Professor Liu Yuanhao, Chairman of Neuboron, signed the agreement on behalf of both parties. This technical cooperation covers multiple aspects such as equipment procurement, BNCT center preparation, BNCT clinical registration, technical support, and operation cooperation. Through sincere cooperation between the two parties, the hospital will maintain its long-term technological advantages and lay a solid foundation for its long-term development.
At the beginning of the ceremony, Mr. Zheng Youshui, Executive Director of Chaoshan Hecheng Hospital, extended a warm welcome and sincere thanks to all guests present on behalf of the hospital. In his speech, Chairman Zheng expressed his wish to invest in building a large-scale hospital in his hometown and his sense of responsibility to give back to his roots. He expected to contribute to the medical cause of his hometown, with no intention of making profits or recovering investment quickly, and would provide strong financial support for the hospital's construction. In particular, taking the lead in introducing the first set of BNCT equipment in eastern Guangdong and cooperating with Neuboron, a leading Chinese BNCT enterprise, will bring new hope and higher-quality medical services to cancer patients in eastern Guangdong.
During the signing ceremony, President Su Bo, in charge of the preparation of Chaoshan Hecheng Hospital, gave a detailed introduction to the hospital's planning and construction blueprint, covering the hospital's basic information, design and construction progress, and preparation plan in a comprehensive manner. Professor Liu Yuanhao, Chairman and Chief Scientist of Neuboron, delivered a report on the application and prospects of BNCT technology, in-depth analyzing the advantages and potential of BNCT as a new generation of precision cancer treatment technology that countries around the world are competing to develop. Finally, President Geng Qingshan of Shenzhen People's Hospital presided over the discussion and exchange among the participating expert representatives, providing valuable suggestions and support for the hospital's construction and future operation and development.
Chaoshan Hecheng Hospital is a major construction project in Chaonan District, Shantou City, to fully implement the "1+1+9" work plan of the CPC Guangdong Provincial Committee and the work requirements of the CPC Shantou Municipal Committee. It is committed to building a high-end medical service platform in eastern Guangdong. Focusing on "cancer and geriatric diseases" and featuring "large specialized departments and small comprehensive services", the hospital meets the multi-level medical needs of eastern Guangdong. Its construction officially started in February 2023 and is planned to open in February 2026.
As a leading enterprise in the BNCT field, Neuboron owns world-class BNCT equipment, integrated diagnosis-treatment boron-targeted drugs, and BNCT-specific treatment planning software. It focuses on providing a complete BNCT solution covering hardware, drugs, software, technical support, and operation guarantee.
This signing cooperation marks a key step in the clinical application and industrialization process of Neuboron's BNCT technology. It will further consolidate Neuboron's leading position in the BNCT industry, expand its market reach, and lay a solid foundation for sustained innovative development. By introducing Neuboron's BNCT technology, Chaoshan Hecheng Hospital can not only improve its cancer treatment level and fill the gap in precision cancer treatment in eastern Guangdong, but also attract more cancer patients to seek medical treatment, enhance the hospital's reputation and competitiveness, and inject strong impetus into the hospital's long-term development.
In the future, the two parties will work together to carry out all-round cooperation in the promotion and application of BNCT technology, scientific research innovation, and talent training. They will jointly explore new frontiers in the medical field, provide another BNCT technology research cooperation platform and academic hub for China and even the world, jointly build a regional benchmark for cancer treatment, and provide high-end cancer medical services for patients.
